Stryker Corp. (NYSE:SYK) and Boston Scientific Corp. (NYSE:BSX) are in "advanced talks" over a possible $1.4 billion deal for Boston Scientific’s pain management business, according to a Bloomberg News report.
A separate deal for Boston Scientific’s neurovascular unit could be "several weeks away," according to the news service, possibly for as much as $1.0 billion.